Objectives:

1. Understand key clinical takeaways from the DAPA-HF trial
2. Explore the cardiovascular benefits of SGLT2 inhibitors demonstrated in clinical trials
3. Compare the benefit of dapagliflozin to other guideline-directed medications for heart failure
4. Evaluate dapagliflozin’s place in therapy for patients with heart failure

Taylor Hodle, PharmD 
PGY1 Pharmacy Resident
Pharmacist
Baystate Medical Center 

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.